Sandoz CEO slams EU-wide drug price proposal, warns US tariffs will hurt patient access
By Maggie Fick
LONDON (Reuters) -The chief executive of generic drugmaker Sandoz said a proposal by the CEOs of Novartis and Sanofi to introduce a Europe-wide list price for new medicines is "deeply flawed" and would not solve global pricing inequities.
Richard Saynor told Reuters that the proposal - outlined in a letter to the Financial Times last week - ignores structural drivers of high drug prices in the United States.
"It made me smile, made me laugh," Saynor said of the proposal, adding that he thinks the Trump administration will succeed in driving down prices for brand-name medicines. But he said big pharmaceutical companies should not respond by hiking prices in Europe, which would hurt patient access.
Saynor argued that U.S. patients have long borne a disproportionate share of costs for innovative medicines, while large drugmakers maintain high margins.
He cited Amgen's autoimmune treatment Enbrel, which costs $70,000 per patient per year in the U.S., compared with $7,000 in Europe.
Earlier this month, Sandoz filed a U.S. antitrust lawsuit against Amgen, alleging the company blocked biosimilar competition, including Sandoz's own version. Biosimilars are near-identical copies of complex biologic drugs whose patents have expired.
Saynor said some form of U.S. price reform is inevitable, pointing to President Donald Trump's stalled plan to link drug prices to international benchmarks during his first term. Reuters reported last week that the Trump administration is again weighing such a move.
Saynor said the structure of the U.S. healthcare system - including pharmacy benefit managers - inflates prices and he likened PBMs to "leeches sucking value out of healthcare".
Generic drugs account for more than 90% of prescriptions filled in the U.S. but just 17% of spending, according to the Association for Accessible Medicines, the main generic medicines trade body. Saynor said greater use of generic and biosimilar drugs could help fund access to genuine innovation, rather than sustaining high prices for older, patent-protected medicines.
Swiss-headquartered Sandoz, which spun off from Novartis in 2023, is one of the world's largest makers of generic and biosimilar drugs. The company sells anti-infectives and generic narcotics for hospital use in the United States.
Saynor said Sandoz's North America President Keren Haruvi, who also chairs the AAM, has been meeting with White House officials nearly every week to discuss pharmaceutical imports and U.S. reliance on foreign drug production.
"They have some really tough choices to make about security of supply ... and I'm quite optimistic these are the right conversations to have ... about accessibility, affordability," he said.
He warned that if significant tariffs are imposed, Sandoz could be forced to withdraw some products from the U.S. market.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
26 minutes ago
- Forbes
GM's $4 Billion Gamble - Gas Guzzlers Or Electric Future?
General Motors, a flagship of the U.S. auto industry for 117 years, has quietly shifted its bold electric-vehicle ambitions. Just a week ago, the company announced a $4 billion investment to ramp up production of gasoline-powered SUVs and trucks at plants in Michigan, Kansas, and Tennessee—aimed at countering flagging EV demand and mitigating U.S. tariffs. Lafayette - March 12, 2024: Chevrolet Tahoe 4WD Z71 display at a dealership. Chevy offers the Tahoe ... More in LS, LT, RST and Premier models. MY:2024 New President = new plans Once GM pledged to go 'all-electric by 2035', riding the momentum of the Inflation Reduction Act and Biden-era clean energy enthusiasm. But EV sales in the U.S. have softened, Washington's EV subsidies are under threat and tariffs are forcing auto companies to rethink their supply chains. Also, by this time, most everyone who had been thinking about buying an EV has bought one, insiders say. The novelty has worn off. Some have simply shrugged and gone back to either all-gas-powered vehicles, hybrids or PHEVS. GM will relocate full-size gas SUV and light-duty truck production to its Orion Assembly in Michigan, redirect the Chevrolet Blazer to Spring Hill, Tennessee, and bring the popular Chevy Equinox back to Fairfax, Kansas, reconfiguring plants that were previously set for EV output, Meanwhile, its Tonawanda, NY plant gets an $888 million investment to produce V‑8 engines—not electric motors. Why Now? Analysts Sam Abuelsamid (Telemetry) argue GM's 'all-electric by 2035' pledge was always conditional—dependent on generous federal EV incentives and solid consumer demand. With both eroding, GM is hedging its bets, and you can't blame them. The Trump administration further complicated matters with 25% tariffs on vehicles and parts from Mexico. By shifting production to U.S. facilities, GM avoids those costs—an immediate financial relief during a tumultuous market. GM says they're not abandoning EVs This isn't an EV abandonment, GM insists. CEO Mary Barra reaffirmed that an electric future remains central, but the company must remain 'responsive to where the customer is." At a recent Wall Street Journal event, she stressed that infrastructure limitations and consumer affordability still impede widespread EV adoption. Still, GM's U-turn complicates its narrative. Just days earlier, the company urged employees to lobby against California's EV mandate, describing it as disconnected from 'market realities' and threatening vehicle affordability. What are the broader implications? GM joins rivals like Volkswagen and Mercedes, which have scaled back their electrification timetables. Industry experts see this as recognition that while EVs are part of the future, they aren't (yet) the only future. Here's what GM's new position really means: For EV adoption - This signals government policy isn't enough. Automakers need stable incentives and reliable infrastructure to build real EV demand. For domestic jobs - Short-term, the gas engine investment creates U.S. manufacturing jobs and protects against import tariffs. Longterm? GM is now playing both offense and defense—building more ICE vehicles to stay profitable while maintaining EV capacity for when conditions improve. The bottom line is that GM's shift is pragmatic, not ideological or a declaration of 'Drill, baby, drill!' It's a response to market and policy uncertainty—but it also represents a retreat from the aspirational vision of a fully electric future.
The Hill
31 minutes ago
- The Hill
Trump in wake of Iran attack: ‘Everyone, keep oil prices down'
In the wake of the U.S. attack on Iranian nuclear facilities, President Trump on Monday urged 'everyone' to keep oil prices down. 'EVERYONE, KEEP OIL PRICES DOWN. I'M WATCHING! YOU'RE PLAYING RIGHT INTO THE HANDS OF THE ENEMY. DON'T DO IT!' Trump said on Truth Social. Oil is traded on a global market, and the energy produced in not only the U.S. but in players around the world including Iran, Russia and Saudi Arabia contribute to the prices that Americans pay at the pump. Prices have spiked in recent days amid escalations between the U.S. and Iran — and gasoline prices were up an average of 8 cents compared to a week ago, according to the American Automobile Association. The $3.22 cent average price was still well below highs in 2022 when the national average was as high as $5 per gallon. Iranian state media reported Sunday that Tehran is considering a closure of the Strait of Hormuz, through which much of the world's oil supply flows, threatening further price increases. Trump also wrote on social media calling on the Department of Energy to drill quickly. 'To The Department of Energy: DRILL, BABY, DRILL!!! And I mean NOW!!!' he added on Truth Social. The Energy Department is primarily a research and funding agency — and is also tasked with maintaining the nation's nuclear weapons stockpile. Unlike many countries, the U.S. does not have a state-run oil company, so the government cannot make the unilateral decision to try to drill. It is up to private companies whether they want to produce oil in the U.S., though some government agencies such as the Interior Department can try to make it more attractive to drill on public lands. Presidents have relatively little influence on oil and gasoline prices generally. —Alex Gangitano contributed.
Bloomberg
31 minutes ago
- Bloomberg
Irish Regulator Warns Against Caving to Pressure on Bank Rules
Ireland's top banking supervisor warned of a need to stick with high standards of financial regulation particularly now when there is increasing pressure to ease them amid trade wars, geopolitical tensions and fears for global growth. 'If we're trying to chase growth with a deregulation engine I don't think that's going to end well for anybody,' Mary-Elizabeth McMunn, Deputy Governor for Financial Regulation at the Central Bank of Ireland, said at Bloomberg's Future of Finance event in Dublin. 'It also can't be that you simplify things just to such a degree that you really fail to capture complex risks.'
